ישראל - עברית - Ministry of Health

גילקו פארם בעמ - שמן טיפולי להזנה והחייאת העור לידיים ורגליים

ישראל - עברית - Ministry of Health

teva israel ltd - filgrastim - תמיסה להזרקה\אינפוזיה - filgrastim 0.6 mg/ml - filgrastim - filgrastim - tevagrastim is indicated for the reduction in the duration of neutropenia and the incidence of febrile neutropenia in patients treated with established cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes ) and for the reduction in the duration of neutropenia in patients undergoing myeloablative therapy followed by bone marrow transplantation considered to be at increased risk of prolonged severe neutropenia. the safety and efficacy of tevagrastim are similar in adults and children receiving cytotoxic chemotherapy. tevagrastim is indicated for the mobilisation of peripheral blood progenitor cells in normal donors (allogeneic pbpc). in patients children or adults with severe congenital neutropenia cyclic or idiopathic neutropenia with an absolute nuetrophil count (anc) less than or equal to 0.5 x 1000000000 /l and a history of severe or recurrent infections long term administration of tevagrastim is indicated to increase neutophil count and to red

ישראל - עברית - Ministry of Health

abbott medical laboratories ltd, israel - pancreatin - קפסולות - pancreatin 300 mg - multienzymes (lipase, protease etc.) - multienzymes (lipase, protease etc.) - for the treatment of pancreatic exocrine insufficiency.

ישראל - עברית - Ministry of Health

abbott medical laboratories ltd, israel - pancreatin - קפסולות - pancreatin 150 mg - multienzymes (lipase, protease etc.) - multienzymes (lipase, protease etc.) - pancreatic exocrine insufficiency.

ישראל - עברית - Ministry of Health

megapharm ltd - trospium chloride - טבליות מצופות - trospium chloride 20 mg - trospium - trospium - symptomatic treatment of urge incontinence and /or increased urinary frequency and urgency as may occur in patients with overactive bladder (e.g. idiopathic or neurologic detrusor overactivity) .

ישראל - עברית - Ministry of Health

roche pharmaceuticals (israel) ltd - capecitabine 150 mg - film coated tablets - capecitabine - adjuvant colon cancer: xeloda is indicated for the adjuvant treatment of patients following surgery of stage iii (dukesע stage c) colon cancer. colorectal cancer: xeloda is indicated for the treatment of patients with advanced or metastatic colorectal cancer advanced gastric cancer: xeloda is indicated for first line treatment of advanced gastric cancer in combination with chemotherapy breast cancer combination therapy: xeloda in combination with docetaxel is indicated for the treatment of patients with metastatic breast cancer after failure of prior anthracycline-containing chemotherapy. breast cancer monotherapy: xeloda is also indicated for the treatment of advanced or metastatic breast cancer after failure of standard therapy including a taxane unless therapy with a taxane is clinically contraindicated.

ישראל - עברית - Ministry of Health

roche pharmaceuticals (israel) ltd - capecitabine 500 mg - film coated tablets - capecitabine - adjuvant colon cancer: xeloda is indicated for the adjuvant treatment of patients following surgery of stage iii (dukesע stage c) colon cancer. colorectal cancer: xeloda is indicated for the treatment of patients with advanced or metastatic colorectal cancer advanced gastric cancer: xeloda is indicated for first line treatment of advanced gastric cancer in combination with chemotherapy breast cancer combination therapy: xeloda in combination with docetaxel is indicated for the treatment of patients with metastatic breast cancer after failure of prior anthracycline-containing chemotherapy. breast cancer monotherapy: xeloda is also indicated for the treatment of advanced or metastatic breast cancer after failure of standard therapy including a taxane unless therapy with a taxane is clinically contraindicated.

ישראל - עברית - Ministry of Health

amgen europe b.v. - filgrastim - תמיסה להזרקה - filgrastim 30 mu/ml - filgrastim - filgrastim - - reduction in the duration and severity of neutropenia in patients treated with highly myelosuppressive chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes ).- reduction in the duration of neutropenia in patients undergoing high-dose cytotoxic chemotherapy followed by bone marrow transplantation. - in children or adults with severe congenital neutropenia cyclic neutropenia or idiopathic neutropenia a history of clinically important infections within the last 12 months and three documented episodes of neutropenia (with an anc< 5 x 1000000000) long-term administration of neupogen is indicated to increase neutrophil counts and to reduce infections. - neupogen is indicated for the mobilisation of autologous peripheral blood progenitor cells alone or following myelosuppressive chemotherapy and the mobilisation of peripheral blood progenitor cells in normal donors (allogeneic pbpc).

ישראל - עברית - Ministry of Health

amgen europe b.v. - filgrastim - תמיסה להזרקה - filgrastim 48 mu / 0.5 ml - filgrastim - filgrastim - - reduction in the duration and severity of neutropenia in patients treated with highly myelosuppressive chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes ).- reduction in the duration of neutropenia in patients undergoing high-dose cytotoxic chemotherapy followed by bone marrow transplantation. - in children or adults with severe congenital neutropenia cyclic neutropenia or idiopathic neutropenia a history of clinically important infections within the last 12 months and three documented episodes of neutropenia (with an anc< 5 x 1000000000) long-term administration of neupogen is indicated to increase neutrophil counts and to reduce infections. - neupogen is indicated for the mobilisation of autologous peripheral blood progenitor cells alone or following myelosuppressive chemotherapy and the mobilisation of peripheral blood progenitor cells in normal donors (allogeneic pbpc).

ישראל - עברית - Ministry of Health

amgen europe b.v. - filgrastim - תמיסה להזרקה - filgrastim 30 mu / 0.5 ml - filgrastim - filgrastim - - reduction in the duration and severity of neutropenia in patients treated with highly myelosuppressive chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes ).- reduction in the duration of neutropenia in patients undergoing high-dose cytotoxic chemotherapy followed by bone marrow transplantation. - in children or adults with severe congenital neutropenia cyclic neutropenia or idiopathic neutropenia a history of clinically important infections within the last 12 months and three documented episodes of neutropenia (with an anc< 5 x 1000000000) long-term administration of neupogen is indicated to increase neutrophil counts and to reduce infections. - neupogen is indicated for the mobilisation of autologous peripheral blood progenitor cells alone or following myelosuppressive chemotherapy and the mobilisation of peripheral blood progenitor cells in normal donors (allogeneic pbpc).